Company: DRTSW
Filing Date: 2025-04-28
Form Type: 424B5
Source: 0001213900-25-035799
Chunk: 19

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-04-28
Form: 424B5
Chunk 19
---
 improvements and capital investments, operational performance,
future market conditions or economic performance and developments in the capital and credit markets and expected future financial performance.

Forward-looking statements involve a number of
risks, uncertainties and assumptions, and actual results or events may differ materially from those projected or implied in those statements.
Important factors that could cause such differences include, but are not limited to:

| ● | We have incurred significant losses since inception and expect                                                                              
 to incur losses over the next several years. Accordingly, we may not be able to achieve or sustain revenues or profitability in the future; |

| ● | We may need substantial additional funding, and if we are                                                                             
 unable to raise capital when needed, we could be forced to delay, reduce or terminate the development of the Alpha DaRT technology or 
 other product discovery and development programs or commercialization efforts;                                                        |

| ● | Our limited operating history may make it difficult for you                         
 to evaluate the success of our business to date and to assess its future viability; |

| ● | Our approach to the development of its proprietary Alpha                                                                             
 DaRT technology represents a novel approach to radiation therapy, which creates significant and potentially unpredictable challenges 
 for us;                                                                                                                              |

| ● | The commercial success of our Alpha DaRT technology, if authorized                                                                                 
 or certified for commercial sale, will depend in part upon public perception of radiation therapies, and to a lesser extent, radiopharmaceuticals, 
 and the degree of their market acceptance by physicians, patients, healthcare payors and others in the medical community;                          |

| ● | The market opportunities for our Alpha DaRT technology may be smaller than anticipated or may be limited to those patients who are               
 ineligible for or have failed prior treatments. If we encounter difficulties enrolling patients in our clinical trials, our clinical development 
 activities could be delayed or otherwise adversely affected;                                                                                     |

| ● | We do not currently engage in commercial marketing activities or sales efforts and have no experience in marketing our products. If       
 we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our Alpha DaRT 
 technology, if approved or certified for commercial sale, we may not be able to generate product revenue;                                 |

| ● | We currently conduct and in the future intend to continue conducting pre-clinical studies, clinical trials for our Alpha DaRT technology   
 outside the United States, and the FDA and similar foreign regulatory authorities or notified bodies may not accept data from such trials; |

<div align='center'>S-10